Publications by authors named "Jes B Hansen"

Claim this Profile
R
Real-world dose adjustments of biologic treatments in psoriasis and their economic impact: a Swedish national population study.
Alexander Egeberg, Jonatan Freilich, M Natalia Stelmaszuk, Rikke Kongerslev, Eydna Apol, Jes Birger Hansen

Clin Exp Dermatol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
Georgios Kokolakis, Kasper Vadstrup, Jes B Hansen, Jose Manuel Carrascosa

Dermatology· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors.
Georgios Kokolakis, Kasper Vadstrup, Jes B Hansen, Jose Manuel Carrascosa

Dermatol Ther (Heidelb)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study.
Marcus Schmitt-Egenolf, Jonatan Freilich, Natalia M Stelmaszuk-Zadykowicz, Eydna Apol, Jes B Hansen

Dermatol Ther (Heidelb)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison.
Philip Hampton, Emma Borg, Jes Birger Hansen, Matthias Augustin

Psoriasis (Auckl)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab.
Jo Lambert, Jes Birger Hansen, Anne Sohrt, Luis Puig

Dermatol Ther (Heidelb)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials.
Karen A Veverka, Jes B Hansen, Maria Yaloumis, Leon Kircik, Linda Stein Gold

J Drugs Dermatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment responder analysis in actinic keratosis: can it lead the way to individualized choice of treatment?
Lutz Schmitz, Jes B Hansen, Mike Bastian, Thomas Larsson, Eggert Stockfleth

J Dermatolog Treat· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641-649.
Jashin J Wu, Jes B Hansen, Dharm S Patel, Nanna Nyholm, Karen A Veverka

J Med Econ· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
Jean-Philippe Lacour, Anthony Bewley, Edward Hammond, Jes B Hansen, Laura Horne

Dermatol Ther (Heidelb)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis.
Jes B Hansen, Thomas Larsson, Nikeshia Dunkelly-Allen, Karen A Veverka, Steven R Feldman

J Drugs Dermatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.
Linda Stein Gold, Jes B Hansen, Dharm Patel, Karen A Veverka, Bruce Strober

J Am Acad Dermatol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
Jashin J Wu, Jes B Hansen, Dharm S Patel, Nanna Nyholm, Karen A Veverka

J Med Econ· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Fixed-combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study.
Dharm S Patel, Karen A Veverka, Jes B Hansen, Paul S Yamauchi, Javier Alonso-Llamazares

J Clin Aesthet Dermatol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetes care may be improved with Steno Quality Assurance Tool--a self-assessment tool in diabetes management.
Ulla Bjerre-Christensen, Annemette Anker Nielsen, Christian Binder, Jes B Hansen, Ebbe Eldrup

Diabetes Res Clin Pract· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
Paul Valensi, Joseph Shaban, Marian Benroubi, Ryuzo Kawamori, Vito Borzì, Jes B Hansen

Curr Med Res Opin· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study.
Leo Niskanen, Antti Virkamäki, Jes B Hansen, Tero Saukkonen

Diabetes Res Clin Pract· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.
Paola Fernandez Vojvodich, Jes B Hansen, Ulf Andersson, Lars Sävendahl, Stefan Hagelberg

J Rheumatol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis